Original Article
3,4-oxo-isopropylidene-shikimic acid inhibits cerebral ischemia-induced oxidative stress and neuronal apoptosis in rats

Ling-Ling Tang1,2, Jing-Ya Ye3, Sheng-Nan Jiang3, Jie-Sheng Zheng3

1State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, China; 2Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou 310058, Zhejiang, China; 3Department of Neurosurgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, China

Received July 7, 2016; Accepted November 5, 2016; Epub April 15, 2017; Published April 30, 2017

Abstract: Background: To investigate the potential protective effects of 3,4-oxo-isopropylidene-shikimic acid (ISA) on brain ischemic injury in rats. Methods: Cell Counting Kit-8, flow cytometry, and TUNEL were used to evaluate the cell viability and the apoptosis rate in vitro and in situ. Reactive oxygen species generation was determined by DCFH-DA assay. qPCR and Western blot were used to test the molecular mechanisms related to the anti-apoptosis effects. Result: Protective effect of pre-conditioning of ISA on the brain injury caused by ischemia was observed. ISA treatment showed anti-apoptosis effects on isolated primary astrocytes and neurons. ROS generation was also significantly scavenged by treatment of ISA. The treatment with ISA protected astrocytes from hypoxic condition-induced apoptosis and ischemic injury. The underlying mechanisms revealed by qPCR and WB showed that the level of mRNA and protein expression of Bax, Bcl-2, and caspase-3 were significantly down-regulated by ISA treatment (P < 0.05). Pre-conditioning with ISA is beneficial in reducing the neuronal damage caused by brain ischemia. Conclusion: Treatment with ISA reduces apoptosis and ROS over-generation caused by ischemic injury. Pre-conditioning with ISA resulted in significantly protective effects on brain under ischemic condition.

Keywords: 3,4-oxo-isopropylidene-shikimic acid, ischemia, apoptosis, oxidative stress, ROS

Introduction
Stroke is a leading cause of disability and death in most industrialized countries [1]. During the pathologic process of stroke, ischemic injury occurs first, and is usually followed by cerebral edema, which worsens the clinical situation. Progress has been made during decades of research focusing on the pathophysiology, risk factors, underlying mechanisms, and effective treatments for stroke [2, 3]; however, the morbidity and mortality of stroke remains high. Therefore, more effective intervention methods and treatments for stroke need to be developed.

The rapidly responding intravenous compound, 3,4-oxo-isopropylidene-shikimic acid (ISA), is usually used for anesthesia among clinical practices. Studies have shown that ISA treatment is protective in brain ischemic injuries and improves the outcome of neurologic conditions [4, 5]. Even though a number of studies have been conducted to determine the mechanism underlying the protective effects of shikimic acid on cerebral ischemia, the detailed mechanism is still unclear. Nevertheless, the potential mechanism may include the antioxidant activity of shikimic acid, a decrease in cerebral metabolism, inhibition of aquaporin-4 expression, and regulation of neuronal apoptosis by modulating neurotransmitters [6-9]. The mechanism underlying the protective effects of shikimic acid is also associated with the property of reducing neuronal apoptosis. It has also been reported that shikimic acid can increase cerebral blood flow, thus facilitating autoregulation in the brain [10]. Few studies have been conducted describing ISA pre-conditioning in protecting against cerebral ischemia.

Neuronal apoptosis is one of the mechanisms, which explains the damage caused by cerebral ischemia. Programmed cell death (PCD) is a
necessary and regulatory process of all cell types in the human body. Under several pathologic conditions, such as cerebral ischemia, neuronal apoptosis will be activated, thus leading to damage of cerebral function [11]. Different molecular mechanisms are involved in this process, among which c-jun N-terminal kinase (JNK) is one of the most crucial pathways [12]. Apart from neurons, the role of astrocytes is often neglected. As the most abundant non-neuronal cell in the central nervous system (CNS), astrocytes account for approximately one-half of the brain volume in humans. Ischemic injury, as a cause of astrocyte apoptosis, should also be considered to understand the mechanism underlying the protective effects of shikimic acid. It is thought that astrocytes are important in maintaining neuronal survival during cerebral ischemia [13]. For this reason, the effects of brain ischemia on astrocytes are worthy to be understood.

For the first time, we tested the protective effects of ISA pre-conditioning in the treatment of cerebral ischemic injury. We focused on neuronal and astrocyte apoptosis induced by ischemia, and also tested the antioxidant effects of the pre-conditioning combination.

Materials and methods

This work was supported by the Ethic Committee of The First Affiliated Hospital of the College of Medicine of Zhejiang University.

Reagents

Dulbecco’s Modified Eagle Medium (DMEM) and fetal bovine serum (FBS) were purchased from Gibco (Life Technologies, USA). Penicillin-streptomycin solution was obtained from Hyclone (Thermo Scientific, USA), 2’, 7’-dichlorofluorescein diacetate (DCFH-DA) was obtained from Molecular Probes (Eugene, OR, USA), and ISA was obtained from Sigma-Aldrich (NY, USA).

Animals

Male Wistar rats (6-8 weeks old) were purchased from the Shanghai Experimental Animal Center (Shanghai, China). Experimental procedures were approved and performed according to the Animal Experimental Center of the First Affiliated Hospital of Zhejiang University Guidelines of Laboratory Animal Care and Use. All efforts were made to reduce the number of animals tested and suffering.

ISA pre-conditioning

The rats were divided into groups as follows: group 1, control group; group 2, rats treated with ISA [1 mg/kg]); group 3, rats treated with ISA [5 mg/kg]); and group 4, rats treated with ISA [10 mg/kg]). ISA was first dissolved in DMSO before intravenous injection for each group. DMSO with shikimic acid was then added to a normal saline solution; the control group was treated with normal saline alone.

Cell culture

Primary astrocytes were collected from the brains of newborn rats according to the following procedures. Cerebral cortices were removed and the tissues were blocked for 15 min after removal of all white matter. The dissociated cells were collected and diluted in DMEM medium with 10% FBS and 1% penicillin and streptomycin. Harvested cells were seeded at a density of 10^6 cells/flasks. Cells were then cultured for 2 weeks in an incubator with 5% CO₂ and 95% at 37°C. During the replacement of medium, loosened cells were removed as oligodendrocytes and other glial cells.

Infarct and edema assessment

An ischemic model was prepared for 12, 24, or 48 h before sacrifice for infarction and edema assessment. After sacrifice, the brain was removed immediately and put in a normal saline solution at 4°C. Brains were then sliced in 2-mm coronal sections and immersed in triphenyl tetrazolium chloride (TTC) to reveal the infarct damage. The brain slices were immersed for 15 min at 37°C and were then placed in 4% formaldehyde. The infarct damage area was determined by image J software. The volume of infarction was calculated according to the formula used in previous studies [6, 12, 14]. The brain water content was also determined to assess edema. The water content in each hemisphere was identified by the ratio of wet-to-dry weight and calculated according to previous studies [15, 16].

Cell proliferation and viability assay

Primary isolated astrocytes were seeded (2 × 10^3 per well) into 96-well plates and were cul-
Effect of 3,4-oxo-isopropylidene-shikimic acid

Table 1. Primer sequences for qPCR

<table>
<thead>
<tr>
<th>Primers</th>
<th>Forward</th>
<th>Reverse</th>
<th>Tm (°C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bax</td>
<td>5'-GGGGATTACCAACAT-3'</td>
<td>5'-CTGGAAGCAGCCAC-3'</td>
<td>59</td>
</tr>
<tr>
<td>Bcl-2</td>
<td>5'-ACCCGGACGTTTATGTC-3'</td>
<td>5'-GGCATCGCTCGCAG-3'</td>
<td>61</td>
</tr>
<tr>
<td>Caspase-3</td>
<td>5'-ATGCCAATCCAGACCGAC-3'</td>
<td>5'-ATCCCCAATCACAAAAACAGC-3'</td>
<td>60</td>
</tr>
<tr>
<td>Caspase-8</td>
<td>5'-AGCAAAGGACAGGGAG-3'</td>
<td>5'-CAGCGTCAACAAAGG-3'</td>
<td>62</td>
</tr>
<tr>
<td>β-actin</td>
<td>5'-TCCCTGATGCTTCGT-3'</td>
<td>5'-ATGCACGAGCATT-3'</td>
<td>61</td>
</tr>
</tbody>
</table>

Culture overnight. Cells were incubated with ISA in advance as pre-conditioning. Culture medium was removed the next day and fresh medium was added. Cell proliferation and viability were evaluated on days 1, 3, and 5 using Cell Counting Kit-8 (CCK8; Dojindo, Japan) reagent according to the manufacturers’ instructions. The absorbency of cells was measured using a 96-well plate reader at 450 nm.

Cell apoptosis assay

Ad/hIFN-λ-induced apoptosis of HSC-3 and Tca8113 cells was detected by FCM with an Annexin V-FITC Apoptosis Detection Kit (KeyGEN) following the manufacturer’s instructions. One hundred microliters of a 10⁵ cell/ml suspension was stained with kit solution (Annexin-V-FITC and PI) in the dark for 15 min. The apoptosis rate was assayed using FACSCalibur Flow Cytometry (BD, USA) at 488 nm.

TUNEL assay

The terminal deoxynucleotidyl-transferase-mediated dUTP nick-end labeling (TUNEL) assay was adopted to determine the apoptosis rate in situ. Brain slices were first fixed with 4% formaldehyde, then permeated with Triton-X. TUNEL staining was then performed according to the manufacturer’s instructions. Nuclei were then labeled with 4',6-diamidino-2-phenylindole (DAPI), and slices were observed with fluorescent microscopy. The mean value of TUNEL-positive cells was counted in each group.

Reactive oxygen species (ROS) assay

Primary astrocytes (5 × 10⁵ cells/well in 96-well plates) were cultured in DMEM medium supplemented with 10% FBS and 1% antibiotics and containing ISA for 24 h as pre-conditioning, and each well was replaced with DMEM medium supplemented with 10% FBS and 1% antibiotics. The intracellular ROS level was measured using 2', 7'-dichlorofluorescein diacetate (DC-FH), which can be oxidized into fluorescent DCF. After fixing, the cells were washed in 1 × PBS, and then incubated in the dark for 30 min with 10 μM DCFH-DA. Images were obtained using the fluorescence of DCF by fluorescence microscopy.

Enzyme-linked immunosorbent assay (ELISA)

Cerebral tissues were collected, homogenized, and centrifuged for ELISA assay. Levels of murine TNF-α, IL-1β, and IL-10 were assayed by ELISA according to the manufacturer’s instructions. OD values were measured in an ELISA plate reader at a wavelength of 450 nm. The TNF-α, IL-1β, and IL-10 concentrations of each tissue sample were determined according to the standard curve.

qPCR

Total RNA was isolated using Trizol reagent. Reverse transcriptase and oligo'dT primer were used to prepare cDNA from 1 μg of RNA according the manufacturer’s instructions (Takara, Tokyo, Japan). Two microliters of each cDNA was then used for PCR amplification using primers for Bax, Bcl-2, caspase-3, and caspase-8 (Table 1). The detailed information of primers is shown in Table 1.

Western blot

Cells were lysed in prepared buffer containing 10 mM Tris (pH 7.2), 150 mM NaCl, 5 mM EDTA, 0.1% SDS, 0.5% Triton X-100, and 1% deoxycholic acid. For Western blot, 30 μg of protein samples were subjected to SDS-PAGE, followed by transfer onto PVDF membranes. After blocking in 5% BSA in PBS, membranes were incubated with antibodies against Bax (1:1000), Bcl-2 (1:1000), caspase-3 (1:1000), and β-actin (1:1000) overnight at 4°C, followed by 1
Effect of 3,4-oxo-isopropylidene-shikimic acid

h-incubation with secondary antibody (1:2000). Blot against β-actin served as the loading control.

Statistical analysis

All data were analyzed using SPSS software (version 13.0) and the results are presented as the mean ± SD. Student’s t-test and two-way analysis of variance (ANOVA) were used to assess statistical significance, with P ≤ 0.05 regarded as statistically significant.

Results

ISA pre-conditioning reduces brain edema and infarction volume

The ischemic animal model was prepared in advance, as previously described. Four groups were set according to the experimental plan: group 1, control group; group 2, rats treated with ISA [1 mg/kg]; group 3, rats treated with ISA [5 mg/kg]; and group 4, rats treated with ISA [10 mg/kg]. Animals were sacrificed at different time points (12, 24, and 48 h), and the brains were removed for infarction and edema assessment. Before sacrificing the rats, the body weights and wet weights of brain were also measured. No significant alterations were detected among the four groups (Figure 1A and 1B). The wet weight of brain was then evaluated, which showed that ISA administration alone could significantly down-regulate the brain edema condition caused by ischemia. Pre-conditioning with ISA could further reduce the brain water content (Figure 1C). The infarction rate was consistent with the edematous state, indicating the highest protective effects of group 4 (pre-conditioning group) compared to other groups (Figure 1D).

ISA pre-conditioning decreases pro-inflammatory cytokines release

ELISA assay was then performed to determine the secretion of pro-inflammatory cytokines under ischemic conditions and the potential reverse effects of ISA. Cerebral tissues were collected, homogenized, and centrifuged for an ELISA assay. Levels of murine TNF-α, IL-1β, and IL-10 were then assayed. For the secretion of IL-1β, although the results among different groups varied slightly, a significant decrease in IL-1β release was shown in groups treated with ISA (1 mg/kg) and the pre-conditioning group (Figure 2A). The three experimental groups showed significant alterations in the levels of expression cytokines (IL-10 and TNF-α). Moreover, groups treated with ISA pre-conditioning had the lowest secretion of IL-10 (Figure...
Effect of 3,4-oxo-isopropylidene-shikimic acid

We concluded that preconditioning with ISA inhibits the inflammation caused by ischemic condition.

**ISA pre-conditioning attenuates neuronal and astrocyte apoptosis induced by ischemic injury**

To further explore the potential effects of ISA preconditioning on cell viability and apoptosis of neurons and astrocytes in vivo and in vitro, we performed the CCK 8 test on isolated primary astrocytes from ischemic animal models and TUNEL staining in situ in the CNS of ischemic rats. The cell proliferative ability of isolated primary astrocytes from ischemic rats was partially improved by treatment with ISA at different dosages (Figure 3A and 3B). Pretreatment with ISA yielded the best outcomes, although the data were not statistically significant (Figure 3A and 3B). TUNEL staining was
Effect of 3,4-oxo-isopropylidene-shikimic acid

then performed in situ on sacrificed rats at different time points (12, 24, and 48 h). The results revealed that the TUNEL-positive cell rates were significantly reduced in each of the time points in groups pre-conditioned with ISA (Figure 3C-E). Thus, pre-conditioning with ISA partially reversed the inhibitory effects of ischemia on neurons and astrocytes.

**ISA pre-conditioning reduces early and late apoptosis induced by hypoxia**

To further verify the hypothesis we assumed in the previous result, we then performed FCM to test the early and late cell apoptosis rate of astrocytes in vitro under hypoxic conditions. Primary astrocytes were isolated from ischemic rats after the rats were sacrificed and cells were incubated under normal conditions in DMEM medium with 10% FBS and 1% penicillin and streptomycin. The cultured cells were then transferred to hypoxic conditions for a further 24 h. FCM was then performed to test the early and late cell apoptosis rate (Figure 4A). The early and late cell apoptosis rate of primary astrocytes was inhibited by treatment with ISA. Among the four groups, pre-conditioning with ISA showed the most protective effects under hypoxic condition (Figure 4B and 4C).

**ISA pre-conditioning scavenges ROS generation in brain ischemia**

To better elucidate the underlying mechanism of the protective effects of ISA pre-conditioning on ischemic rats brain injury, we examined ROS generation of isolated astrocytes and neurons in situ. The results were in agreement with our previous results, indicating that pre-conditioning with ISA is protective against over-generation of ROS under ischemic conditions. Primary astrocytes were isolated from the ischemic model at 12, 24, and 48 h to determine ROS scavenging ability within each group (Figure 5A-C). The ROS-positive cell rate in situ showed similar results as pre-conditioning with ISA, and reduced the ROS-positive cell number as well.

**ISA pre-conditioning down-regulates Bax, Bcl-2, and caspase-3 expression**

To better understand the mechanism underlying the protective effects of ISA pre-conditioning against cell apoptosis, we performed qPCR

---

**Figure 4. ISA pre-conditioning reduces both early and late apoptosis induced by hypoxic condition.** ISA pre-conditioning was administered to rats in the ischemic model described in the Methods. A. FCM analysis of the cell apoptosis rate of astrocytes cultured under hypoxic conditions. B. Early apoptosis rate of astrocytes. C. Late apoptosis rate of astrocytes. Data in the figures represent the average ± SD (n = 3). *P < 0.05, compared to the control group.
and Western blot on several of the key signaling molecules. Bax, Bcl-2, and caspase-3 were down-regulated by treatment with ISA, especially in groups pre-conditioned with ISA (Figure 6A). The qPCR results revealed that the level of Bax, Bcl-2, and caspase-3 mRNA were also decreased (Figure 6B and 6C); however, the expression of caspase-8 was not affected by treatment with ISA (Figure 6D).

**Discussion**

In the present study we demonstrated the protective effects of ISA pre-conditioning on ischemic brain injury. We also attempted to explain the detailed mechanism underlying the protective effects by focusing on apoptosis and oxidative stress induced by ischemic injury. We showed that pre-treatment with ISA on isolated primary astrocytes and pre-conditioning with ISA in ischemic rats partially reversed the damage caused by ischemic injury. Thus, ISA has a protective effect on ischemic-induced injury when administered alone; what’s more, the combination of the two has a better outcome compared to other groups.

Astrocytes are the most abundant cells in the CNS, and function as a supporting cell on structure, metabolism, and neuronal activity [17]. The function of astrocytes is intimately related with the normal function of neurons on survival, plasticity, and neuronal activity. Astrocytes are even believed to be an alternative resource for the replacement of neurons in some CNS diseases [18]. During the pathologic process of brain ischemia, astrocytes are affected extensively and apoptosis will be induced [19]. Neuronal function damage is mainly caused by neuronal apoptosis under ischemic conditions [11]. In this regard, apoptosis of neurons and astrocytes is a main focus to explain the mechanism by which ischemia causes damage (Figure 3).

Various molecular mechanisms are involved in the process of neuronal apoptosis, among which the JNK pathway is crucial. The JNK family consists of JNK1, JNK2, and JNK3. Interestingly, JNK3 is only expressed in the CNS, testicular tissues, and heart [20]. During the pathologic process of brain ischemia, JNK3 plays a key role in neuronal apoptosis. It has been reported that JNK knockout mice have reduced brain damage following brain ischemic injury [21, 22]. In the current study we mainly focused on several other apoptosis-related genes (Bax, Bcl-2, and caspase-3). Since few studies have reported the change in expression of the genes in both astrocytes and neurons, we performed qPCR and Western blot analysis...
Effect of 3,4-oxo-isopropylidene-shikimic acid (ISA) to test ischemic/hypoxic injury on these two cell types. As expected, ISA administration can significantly reduce the expression of these apoptosis-related genes on mRNA and protein levels (Figure 6). Moreover, pre-condition with ISA resulted in a better outcome with respect to the cell apoptosis rate of astrocytes and TUNEL staining of neurons in situ (Figures 3 and 4). Our study results are consistent with previous studies involving the inhibitory effects of ISA on neuronal apoptosis induced by ischemia [4, 7, 14, 23-25]; however, we focused on the pre-conditioning with ISA. Moreover, we also evaluated the cell apoptosis rate of astrocytes as a major cell type affected by apoptosis during ischemic injury (Figure 3).

Cell apoptosis induced by ischemic injury has complex mechanisms. Apart from hypoxia, cell death can also be induced by oxidative stress caused by the extensive rate of oxidative metabolism during the pathologic process [26]. ROS are regarded as one of the most crucial and important causes of brain damage after stroke, especially when reperfusion begins [27-29]. Consistently, compounds like antioxidants are helpful in alleviating the injury caused by ischemia [30]. Free radical generation is a continuous process during the onset of stroke and ischemic injury [31]. Over-generation of ROS and free radicals can lead to severe cellular damage, including membrane lipid peroxidation, DNA fragmentation and damage, and protein damage [32]. Cell apoptosis can also be induced by ROS generation, which is similar for brain ischemia [33, 34]. In addition, enzyme activity can also be affected by the abnormal expression and release of ROS, which leads to neuronal cell apoptosis [35, 36]. Thus, we performed ROS generation assessment in situ and on primary astrocytes to determine the effects of ISA on ROS production. Indeed, ISA has antioxidant ability on ROS over-generation and ROS was scavenged more thoroughly in groups pre-conditioned with ISA (Figure 5).

In conclusion, treatment with ISA is beneficial in protecting the neuronal damage caused by brain ischemia (Figure 1). Pre-conditioning with
ISA had better protective effects in our experimental groups. Our findings are instructive for anesthesia procedures involving brain ischemic diseases, such as stroke.

Acknowledgements

This work was supported by the National Natural Science Foundation 81073082 (to Jie-sheng Zheng) and 81172702 (to Ling-ling Tang).

Disclosure of conflict of interest

None.

Address correspondence to: Jie-Sheng Zheng, Department of Neurosurgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Qinchun RD 79, Hangzhou 310003, Zhejiang, China. Tel: 057187236805; Fax: 057187236803; E-mail: jieshengzheng42@sina.com

References

Effect of 3,4-oxo-isopropylidene-shikimic acid


